Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$0.14 - $12.49 $1,403 - $125,199
-10,024 Reduced 11.8%
74,893 $11,000
Q3 2022

Nov 14, 2022

SELL
$8.51 - $13.6 $32,108 - $51,312
-3,773 Reduced 4.25%
84,917 $890,000
Q2 2022

Aug 15, 2022

BUY
$7.31 - $11.85 $534,792 - $866,934
73,159 Added 471.05%
88,690 $859,000
Q4 2021

Feb 11, 2022

BUY
$4.19 - $9.56 $65,074 - $148,476
15,531 New
15,531 $149,000
Q3 2021

Nov 16, 2021

SELL
$3.56 - $4.64 $497,666 - $648,644
-139,794 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$3.95 - $5.41 $191,448 - $262,211
-48,468 Reduced 25.74%
139,794 $604,000
Q1 2021

May 17, 2021

SELL
$4.52 - $7.8 $30,803 - $53,157
-6,815 Reduced 3.49%
188,262 $996,000
Q4 2020

Feb 16, 2021

BUY
$4.37 - $9.46 $26,875 - $58,179
6,150 Added 3.26%
195,077 $1.38 Million
Q3 2020

Nov 13, 2020

BUY
$8.56 - $26.93 $54,356 - $171,005
6,350 Added 3.48%
188,927 $1.71 Million
Q2 2020

Aug 14, 2020

BUY
$21.21 - $31.55 $512,497 - $762,342
24,163 Added 15.25%
182,577 $5.02 Million
Q1 2020

May 15, 2020

BUY
$18.43 - $38.04 $55,879 - $115,337
3,032 Added 1.95%
158,414 $3.49 Million
Q4 2019

Feb 07, 2020

BUY
$29.6 - $43.71 $117,216 - $173,091
3,960 Added 2.62%
155,382 $5.87 Million
Q3 2019

Nov 08, 2019

BUY
$29.87 - $42.22 $185,403 - $262,059
6,207 Added 4.27%
151,422 $4.68 Million
Q2 2019

Aug 09, 2019

BUY
$31.16 - $39.46 $1.59 Million - $2.02 Million
51,076 Added 54.26%
145,215 $5.73 Million
Q1 2019

May 14, 2019

BUY
$19.96 - $38.62 $315,248 - $609,964
15,794 Added 20.16%
94,139 $3.64 Million
Q4 2018

Feb 14, 2019

SELL
$23.57 - $32.33 $29,981 - $41,123
-1,272 Reduced 1.6%
78,345 $1.85 Million
Q3 2018

Nov 13, 2018

BUY
$22.5 - $39.35 $1.79 Million - $3.13 Million
79,617 New
79,617 $2.43 Million

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.